Novel Triazole-based Condensed Derivatives As Putative Anti-cancer Agents | 37486
ISSN: 2167-065X

Clinical Pharmacology & Biopharmaceutics
Open Access

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
Recommended Conferences

34rd World Congress on Pharmacology

Barcelona, Spain
Indexed In
  • CAS Source Index (CASSI)
  • Index Copernicus
  • Google Scholar
  • Sherpa Romeo
  • Genamics JournalSeek
  • RefSeek
  • Hamdard University
  • OCLC- WorldCat
  • Publons
  • Euro Pub
Share This Page

Novel triazole-based condensed derivatives as putative anti-cancer agents

Pharma Middle East

Birsen Tozkoparan1, Peri S Aytac1, Irem Durmaz2 and Rengul Cetin Atalay3

1Hacettepe University, Turkey 2Bilkent University, Turkey 3Middle East Technical University, Turkey

Posters-Accepted Abstracts: Clin Pharmacol Biopharm

DOI: 10.4172/2167-065X.C1.014

Cancer is recently announced as the leading cause of death worldwide. In the next two decades, the number of new cases is expected to rise dramatically. Chemotherapy is employed as a crucial part of the multimodal treatment of cancer. Unfortunately, the lack of selective and efficient agents constitutes a barrier against chemotherapy. Therefore research on the novel chemotherapeutics is receiving continuous interest. Widely-used Non-Steroidal Anti-Inflammatory Drugs’ (NSAIDs’) cancer chemo-preventive effects are demonstrated. Besides this, there are diverse studies asserting anticancer activities of 1,2,4-triazoles and their condensed derivatives. These conclusions inspired us to design novel 1,2,4-triazole-based condensed derivatives incorporating with NSAIDs’ structural motifs, namely 1,2,4-triazolo-[3,4-b]-1,3,4-thiadiazoles, which have been expected to have cytotoxic properties. The mentioned compounds were achieved by the reaction of an aminomercaptotriazole (1) derived from flurbiprofen with appropriate benzoic acids (a-j) in phosphorus oxychloride. Their initial cytotoxicity screening was assayed by NCI-Sulforhodamine B (SRB) test against human liver, breast and colon carcinoma cell lines. Compound 1h was further studied against enlarged hepatocellular carcinoma cell lines. Then, real-time cytotoxic effect of 1h was measured via RT-CES. For corroborating cellular response which 1h caused, cells were observed after staining with immune-fluorescent Hoechst dye. Furthermore, the effect of 1h was analyzed by measuring DNA content of the cell cycle phases with FACS method by using Propidium Iodide. Data showed that there was slight increase in Sub-G1 phase. These observations were helpful to enlighten possible mechanism of action of compound 1h triggered, and encouraged us for further studies.

Birsen Tozkoparan has completed her PhD from Hacettepe University, Faculty of Pharmacy, and Department of Pharmaceutical Chemistry. She had completed her Post-doctoral studies from Westfäelische Wilhelms University, Institute of Pharmaceutical Chemistry, Münster, Germany and North-eastern University, Department of Pharmaceutical Sciences, Boston, USA. She is a Member of Hacettepe University. She has published more than 40 papers, mostly about analgesic/anti-inflammatory and anticancer drug research areas, in prestigious journals. She is Deputy Director of Hacettepe University, Institute of Health Sciences.

Email: [email protected]